Literature DB >> 26259795

Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae.

Ana Carolina R Souza1, Beth Burgwyn Fuchs2, Henrique M S Pinhati3, Ricardo A Siqueira1, Ferry Hagen4, Jacques F Meis5, Eleftherios Mylonakis2, Arnaldo L Colombo6.   

Abstract

Candida parapsilosis is the main non-albicans Candida species isolated from patients in Latin America. Mutations in the ERG11 gene and overexpression of membrane transporter proteins have been linked to fluconazole resistance. The aim of this study was to evaluate the molecular mechanisms in fluconazole-resistant strains of C. parapsilosis isolated from critically ill patients. The identities of the nine collected C. parapsilosis isolates at the species level were confirmed through molecular identification with a TaqMan qPCR assay. The clonal origin of the strains was checked by microsatellite typing. The Galleria mellonella infection model was used to confirm in vitro resistance. We assessed the presence of ERG11 mutations, as well as the expression of ERG11 and two additional genes that contribute to antifungal resistance (CDR1 and MDR1), by using real-time quantitative PCR. All of the C. parapsilosis (sensu stricto) isolates tested exhibited fluconazole MICs between 8 and 16 μg/ml. The in vitro data were confirmed by the failure of fluconazole in the treatment of G. mellonella infected with fluconazole-resistant strains of C. parapsilosis. Sequencing of the ERG11 gene revealed a common mutation leading to a Y132F amino acid substitution in all of the isolates, a finding consistent with their clonal origin. After fluconazole exposure, overexpression was noted for ERG11, CDR1, and MDR1 in 9/9, 9/9, and 2/9 strains, respectively. We demonstrated that a combination of molecular mechanisms, including the presence of point mutations in the ERG11 gene, overexpression of ERG11, and genes encoding efflux pumps, are involved in fluconazole resistance in C. parapsilosis.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26259795      PMCID: PMC4576033          DOI: 10.1128/AAC.01177-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  53 in total

1.  Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia.

Authors:  Emilia Cantón; Javier Pemán; Guillermo Quindós; Elena Eraso; Ilargi Miranda-Zapico; María Álvarez; Paloma Merino; Isolina Campos-Herrero; Francesc Marco; Elia Gomez G de la Pedrosa; Genoveva Yagüe; Remedios Guna; Carmen Rubio; Consuelo Miranda; Carmen Pazos; David Velasco
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

Review 2.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

3.  Accurate identification of Candida parapsilosis (sensu lato) by use of mitochondrial DNA and real-time PCR.

Authors:  Ana Carolina R Souza; Renata C Ferreira; Sarah S Gonçalves; Guillermo Quindós; Elena Eraso; Fernando C Bizerra; Marcelo R S Briones; Arnaldo L Colombo
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

Review 4.  Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature.

Authors:  Florent Morio; Cedric Loge; Bernard Besse; Christophe Hennequin; Patrice Le Pape
Journal:  Diagn Microbiol Infect Dis       Date:  2010-04       Impact factor: 2.803

5.  Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis.

Authors:  Varsha Moudgal; Tania Little; Dina Boikov; Jose A Vazquez
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 6.  Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis.

Authors:  Mohan Pammi; Linda Holland; Geraldine Butler; Attila Gacser; Joseph M Bliss
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

7.  Candida tropicalis antifungal cross-resistance is related to different azole target (Erg11p) modifications.

Authors:  A Forastiero; A C Mesa-Arango; A Alastruey-Izquierdo; L Alcazar-Fuoli; L Bernal-Martinez; T Pelaez; J F Lopez; J O Grimalt; A Gomez-Lopez; I Cuesta; O Zaragoza; E Mellado
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

8.  Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain.

Authors:  Matteo Bassetti; Maria Merelli; Elda Righi; Ana Diaz-Martin; Eva Maria Rosello; Roberto Luzzati; Anna Parra; Enrico Maria Trecarichi; Maurizio Sanguinetti; Brunella Posteraro; Jose Garnacho-Montero; Assunta Sartor; Jordi Rello; Mario Tumbarello
Journal:  J Clin Microbiol       Date:  2013-10-09       Impact factor: 5.948

9.  Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.

Authors:  Michael A Pfaller; Shawn A Messer; Leah N Woosley; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-05-29       Impact factor: 5.948

10.  Brazilian guidelines for the management of candidiasis - a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical.

Authors:  Arnaldo Lopes Colombo; Thaís Guimarães; Luis Fernando Aranha Camargo; Rosana Richtmann; Flavio de Queiroz-Telles; Mauro José Costa Salles; Clóvis Arns da Cunha; Maria Aparecida Shikanai Yasuda; Maria Luiza Moretti; Marcio Nucci
Journal:  Braz J Infect Dis       Date:  2013-05-18       Impact factor: 3.257

View more
  43 in total

Review 1.  Candida parapsilosis: from Genes to the Bedside.

Authors:  Renáta Tóth; Jozef Nosek; Héctor M Mora-Montes; Toni Gabaldon; Joseph M Bliss; Joshua D Nosanchuk; Siobhán A Turner; Geraldine Butler; Csaba Vágvölgyi; Attila Gácser
Journal:  Clin Microbiol Rev       Date:  2019-02-27       Impact factor: 26.132

2.  Evaluation of Two Commercial Broth Microdilution Methods Using Different Interpretive Criteria for the Detection of Molecular Mechanisms of Acquired Azole and Echinocandin Resistance in Four Common Candida Species.

Authors:  Ha Jin Lim; Jong Hee Shin; Mi-Na Kim; Dongeun Yong; Seung A Byun; Min Ji Choi; Seung Yeob Lee; Eun Jeong Won; Seung-Jung Kee; Soo Hyun Kim; Myung-Geun Shin
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

3.  Usefulness of the Non-conventional Caenorhabditis elegans Model to Assess Candida Virulence.

Authors:  Marcelo Ortega-Riveros; Iker De-la-Pinta; Cristina Marcos-Arias; Guillermo Ezpeleta; Guillermo Quindós; Elena Eraso
Journal:  Mycopathologia       Date:  2017-05-18       Impact factor: 2.574

4.  General hospital outbreak of invasive candidiasis due to azole-resistant Candida parapsilosis associated with an Erg11 Y132F mutation.

Authors:  Dora E Corzo-Leon; Mark Peacock; Patricia Rodriguez-Zulueta; Grace J Salazar-Tamayo; Donna M MacCallum
Journal:  Med Mycol       Date:  2021-07-06       Impact factor: 4.076

5.  Evidence of Fluconazole-Resistant Candida parapsilosis Genotypes Spreading across Hospitals Located in Madrid, Spain and Harboring the Y132F ERG11p Substitution.

Authors:  Pilar Escribano; Jesús Guinea; Judith Díaz-García; Ana Gómez; Luis Alcalá; Elena Reigadas; Carlos Sánchez-Carrillo; Ana Pérez-Ayala; Elia Gómez-García de la Pedrosa; Fernando González-Romo; Paloma Merino-Amador; María Soledad Cuétara; Coral García-Esteban; Inmaculada Quiles-Melero; Nelly Daniela Zurita; María Muñoz-Algarra; Isabel Sánchez-Romero; María Teresa Durán-Valle; Aída Sánchez-García; Eva Alcoceba; Patricia Muñoz
Journal:  Antimicrob Agents Chemother       Date:  2022-07-19       Impact factor: 5.938

6.  Candida parapsilosis Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance.

Authors:  Laura A Doorley; Jeffrey M Rybak; Elizabeth L Berkow; Qing Zhang; Joachim Morschhäuser; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2022-06-14       Impact factor: 5.938

7.  Transcriptional Response of Candida auris to the Mrr1 Inducers Methylglyoxal and Benomyl.

Authors:  Amy R Biermann; Deborah A Hogan
Journal:  mSphere       Date:  2022-04-27       Impact factor: 5.029

8.  First Report of Candidemia Clonal Outbreak Caused by Emerging Fluconazole-Resistant Candida parapsilosis Isolates Harboring Y132F and/or Y132F+K143R in Turkey.

Authors:  Amir Arastehfar; Farnaz Daneshnia; Suleyha Hilmioğlu-Polat; Wenjie Fang; Melike Yaşar; Furkan Polat; Dilek Yeşim Metin; Petra Rigole; Tom Coenye; Macit Ilkit; Weihua Pan; Wanqing Liao; Ferry Hagen; Markus Kostrzewa; David S Perlin; Cornelia Lass-Flörl; Teun Boekhout
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

9.  Fluconazole Pharmacokinetics in Galleria mellonella Larvae and Performance Evaluation of a Bioassay Compared to Liquid Chromatography-Tandem Mass Spectrometry for Hemolymph Specimens.

Authors:  Karen Marie Thyssen Astvad; Joseph Meletiadis; Sarah Whalley; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

10.  The efflux pump inhibitor tetrandrine exhibits synergism with fluconazole or voriconazole against Candida parapsilosis.

Authors:  Ya-Jing Zhao; Wei-Da Liu; Yong-Nian Shen; Dong-Mei Li; Kun-Ju Zhu; Hong Zhang
Journal:  Mol Biol Rep       Date:  2019-08-12       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.